Medullary thyroid carcinoma;Le cancer medullaire de la thyroide

Revue de Medecine Interne

Volumn 20, Issue 6, 1999, Pages 490-503

  Modigliani, E ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Calcitonin; Medullary thyroid carcinoma; Multiple endocrine neoplasia type 2; Proto oncogene RET

Indexed keywords

CALCITONIN;

DISEASE ASSOCIATION; DISEASE MARKER; FAMILIAL CANCER; FOLLOW UP; HUMAN; HYPERPARATHYROIDISM; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PROGNOSIS; REVIEW; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; ADRENAL TUMOR; ADULT; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETIC SCREENING; GENETICS; INFANT; MEDULLARY CARCINOMA; MUTATION; PREGNANCY; REOPERATION; THYROID TUMOR; TIME;

ADRENAL GLAND NEOPLASMS; ADULT; CALCITONIN; CARCINOMA, MEDULLARY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GENETIC SCREENING; HUMANS; INFANT; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; PHEOCHROMOCYTOMA; PREGNANCY; PROGNOSIS; REOPERATION; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS;

EID: 0033149923     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(99)80084-8     Document Type: Article

References (68)

1. Modigliani E et le GETC. Le cancer médullaire en France en 1995. Ann Endocrinol 1996 ; 57 : 3-8.
2. Modigliani E. Les néoplasies endocriniennes de type 2. Presse Méd 1998 ; 27 : 627-40.
3. Farndon JR, Leight GS, Dilley WG. Familial medullary thyroid carcinoma without associated endocrinopathies: A new clinical entity. Br J Surg 1986 ; 73 : 278-81.
4. Casanova S, Rosenberg-Bourgin M, Farkas D, CAlmettes C, Feingold N, Heshmati HM, et al. Pheochromocytoma in multiple endocrine neoplasia type 2 A: Survey of 100 cases. Clin Endocrinol (Oxf) 1993 ; 38 : 531-7.
5. Modigliani E, Vasen HFA, Raue K, Dralle H, Frilling A, Gheri RG, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. J Intern Med 1995 ; 238 : 363-7.
6. Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2: European study. J Intern Med 1995 ; 238 : 369-73.
7. Kraimps JL, Denisot A, Carnaille B, Henry JF, Proye C, Bacourt F, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A: A retrospective French multicentric study. Word J Surg 1996 ; 20 : 808-11.
8. Chabre O, Labat F, Pineln Berthod F, Tatel Y, Bachelot I. Cutaneous lesions associated with multiple endocrine neoplasia type 2A: Lichen amyloidisis or notalgia paresthetica. Henry Ford Hosp Med J 1992 ; 40 : 245-8.
9. Caron PH, Attie T, David D, Amiel J, Brousset F, Roger P, et al. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab 1996 ; 81 : 2731-3.
10. Snider RH, Nylen SR, Becker K. Procalcitonin and its compound peptides in systemic inflammation. Immunochemical characterization. J Invest Med 1997 ; 45 : 552-60.
11. Pacini F, Fontanelli M, Fuggazola L, Elisei H, Romei C, Di Coscio G, et al. A. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994 ; 78 : 826-9.
12. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint-André JP, et al. Interest of routine measurement of serum calcitonin (CT): Study in a large series of thyroidectomized patients. J Clin Endocrinol Metab 1997 ; 82 : 338-41.
13. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Yuong Ncoc P, et al. Prevalence of sporadic medullary thyroid carcinoma: The importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 1995 ; 42 : 453-60.
14. La Prise en Charge Diagnostique du Nodule Thyroïdien: Recommandations pour la Pratique Clinique. Paris: Éditions Norbert Attali; 1995. p. 256. [Andem, service des études, p. 15-24].
15. Niccoli P, Conte-Devolx B., Lejeune PJ, Carayon P, Henry JF, Roux F, et al. Les hypercalcitoninémies en dehors des cancers médullaires du corps thyroïde. Ann Endocrinol 1996 ; 57 : 15-22.
16. Franc B, Modigliani E. Le cancer médullaire de la thyroïde: Évolution des concepts. Arch Anat Cytol 1998 ; 46 : 100-11.
17. Franc B. Le cancer médullaire de la thyroïde: La place de l'anatomie pathologique face aux tests génétiques. Rev Fr Lab 1994 ; 270 : 27-36.
18. Gagel RF, Tashjian AHJ, Cummings T, Papathanosopoulos KS, Kaplan HM, De Lellis RA, et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A; an 18 years experience. N Engl J Med 1988 ; 318 : 478-84.
19. Mulligan LM, Kwok JB, Healey CS, Edson MJ, Eng C, Gardner E, et al. Germ line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993 ; 363 : 458-60.
20. Hoftra RMW, Landsvater RM, Ceccerini I. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994 ; 367 : 375-6.
21. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, CAlmettes C, et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994 ; 3 : 1939-43.
22. Bolino A, Schuffenecker I, Luo J, Sen M, Silengo M, TOcco T, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995 ; 10 ; 2415-9.
23. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 international RET mutation consortium analysis. JAMA 1996 ; 276 : 1575-9.
24. Rossel M, Schuffenecker I, Schlumberger M, Bonnardel C, Modigliani E, Gardet P, et al. Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet 1995 ; 95 : 403-6.
25. Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschprung disease. N Engl J Med 1996 ; 335 : 943-51.
26. Schuffenecker I, Virally Monod M, Brohet R, Goldgar D, Conte-Devolx B, LEclerc L, et al. Risk and penetrance of primary hyperparathyroidism in MEN2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 1998 ; 83 : 487-91.
27. Berndt I, Reuter M, Sailer B, Frank-Raue K, Groth P, Gussendorf M, et al. A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and miltiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998 ; 83 : 770-5.
28. Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988 ; i : 397-401.
29. Proye C, Marmousez T. Cancer médullaire de la thyroïde: Moyens thérapeutiques, chirurgie de première intention. In: Calmettes C, Guliana JM, eds. Medullary Thyroid Carcinoma. Paris: John Libbey Eurotext ; 1991. p. 199-206.
30. Samaan N, Schultz PN, Hickey RC. Medullary thyroid carcinoma: Prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988 ; 67 : 801-5.
31. Proye C, Marmousez T, Modigliani E, Calmettes C. Stratégie diagnostique et conduite à tenir dans les hypercalcitoninémies résiduelles après traitement chirurgical du cancer médullaire de la thyroïde. Rev Fr Endocrinol Clin 1993 ; 34 : 549-62.
32. Dralle H, Scheuman GFW, Proye C, Bacourt F, Frilling A, LimBert F, et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: A retrospective, European, multi-centre study. J Intern Med 1995 ; 238 : 357-61.
33. Tisell LE, Hanson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986 ; 99 : 60-6.
34. Murat A. Les moyens de visualisation en cas de CT élevée en post-opératoire. Ann Endocrinol 1996 ; 57 : 27-32.
35. Motte P, Vauzelle P, Gardet P, Ghillani P, Caillou B, ParmenTier C, et al. Construction and clinical validation of a sensitive and specific assay for serum mature using monoclonal anti-peptide antibodies. Clin Chim Acta 1988 ; 174 : 35-54.
36. Cohen R, BUschenschutz B, Estrade P, Gardet P, Modigliani E et le GETC. Causes de mortalité chez les patients atteints de cancer médullaire du corps thyroïde. Presse Méd 1996 ; 25 : 1819-22.
37. Frank-Raue K, Bul H, Dorr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 1995 ; 42 : 31-7.
38. Abdelmoumene N, Schlumberger M, Gardet P, Roche A, Travagli JP, Francese C, et al. Selective venous sampling catheterisation for localization of persisting medullary thyroid carcinoma. Br J Cancer 1994 ; 69 : 1141-4.
39. Bardies M, Bardet S, Faivre-Chauvet, Peltier P, Doublard JY, Mahé M, et al. Bispecific antibody and iodine 131 labeled bivalent hapten dosimetry in patients with medullary thyroid or small cell lung cancer. J Nucl Med 1996 ; 37 : 1853-9.
40. Sarfati E, Halimi B, Wioland M, Delabiolle-Vaylet C, Giriaz A. Cancer médullaire du corps thyroïde: Intérêt de l'immunoscintigraphie et de la chirurgie radio-immunoguidée. Ann Chir 1995 ; 49 : 342-3.
41. Barbot N, Calmettes C, Schuffenecker I, Saint-André JP, Franc B, Rohmer V, et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using a immunoradiometric assay of calcitonin: Comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1994 ; 78 : 114-20.
42. Ferdogan M, Gullu S, Baskai N, Uysal AR, Kamel N, Erdogan G. Omeprazole: Calcitonin stimulation test for the diagnosis and the follow-up and family screening in medullary tyroid carcinoma. J Clin Endocinol Metab 1997 ; 82 : 897-9.
43. Guyetant S, Rousselet MC, Durigon M, Chappard D. Franc B, Gurin O, et al. Sex-related C cell hyperplasia in the normal human thyroid: A quantitative autopsy study. J Clin Endocrinol Metab 1997 ; 82 : 42-7.
44. Wion-Barbot N, Schuffenecker I, Niccoli P, Conte-Devolx B, Lecomte P, Houdent C, et al. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families. Ann Endocrinol 1997 ; 58 : 302-8.
45. Lips CJM, Landswater RM, Hoppener JWH, Geerdink RA, Blighani G, Jansen-Schillhorn-Van Veen JM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine noplasia type 2A. N Engl J Med 1994 ; 331 : 828-35.
46. Wells SA Jr, Chi DD, Toshima K, Dehmer LP, Coffin CM, Dowton B, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994 ; 220 : 237-50.
47. Decker RA, Peacock ML, Borst MT, Sweet JD, Thompson MD. Progress in genetic screening of multiple endocrine neoplasia type 2A: Is calcitonin testing obsolete? Surgery 1995 ; 118 : 257-64.
48. Frilling A, Dralle H, Eng C, Raue F, Broelsch CE. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 1995 ; 118 ; 1999-2004.
49. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancini JF, et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for RET gene mutations. Surgery 1995; 118: 1031-5.
50. Dralle H, Gimm O, Simon D, Raue F, Gortz G, Niéderlé B, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma. German and Austria experience. World J Surg 1998 ; 22 : 744-51.
51. Proye C, Carnaille B, Banhove L. Morbidité de la thyroïdectomie totale chez l'enfant et l'adolescent de moins de 15 ans. Ann Endocrinol 1998 ; 59 : 93-8.
52. Murat A, Modigliani E, Conte-Devolx B, Rohmer V, Leclerc L, Guilhem, I et al. Prise en charge thérapeutique précoce des sujets prédisposés génétiquement au cancer médullaire du corps thyroïde. Ann Chir 1997 ; 52 : 455-60.
53. Guliana Jm et le GETC. Place des thérapeutiques non chirurgicales dans le traitement des patients atteints du CMT. Ann Endocrinol 1996 ; 57 : 33-40.
54. Schlumberger M, Abdelmoumène N, Delisle MJ, Couette Je and the GETC. Treatment of advanced medullary thyroid cancer. Br J Cancer 1995 ; 71 : 363-5.
55. Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Guliana JM, Charpentier G, et al. Results of long term continuous octreotide subcutaneous administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 1992 ; 36 : 183-6.
56. Schlumberger M, Gardet P, De Vathaire F, Sarrazin D, Travagli JP, Parmentrier C. External radiotherapy and chemotherapy in MCT. In: Calmettes C, Guliana JM, eds. Medullary Thyroid Carcinoma. Paris: Inserm/John Libbey Eurotext Ltd; 1991. p. 213-20.
57. COronne C, Pecking A, Croisier JC, Boneu A, Schwartz C, Grol JC, et al. Disappointing results with 131-MIBG therapy for medullary thyroid carcinoma (MTC) in a retrospective french multicentric study. Eur J Nucl Med 1995 ; 22 : 829.
58. Saad ME, Ordoner NG, Rashid RK, Guido JJ, Stratton HU, Hickey RC, et al. Medullary carcinoma of the thyroid: A study of clinical features and prognostic factors in 161 patients. Medicine 1984 ; 63 : 319-42.
59. Bergholm U, Bergström R, Ekbom A. Long term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997 ; 79 : 132-8.
60. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sucliffe S, Panzarella T. Medullary thyroid cancer: Analysis of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996 ; 6 : 305-10.
61. Schröder S, Böcker W, Baisch H, Burk CG, Arps A, Meiners T, et al. Prognostic factors in Medullary thyroid carcinoma. Cancer 1988 ; 62 : 806-16.
62. Bergholm U, Adami Ho, Bergström R, Johanson H, Lindell G, Telenius-Berg M, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: A nationwide study of 249 patients in sweden from 1959 through 1981. Cancer 1989 ; 63 : 1196-204.
63. Raue F, Kotzerke J, Reinwein, Schroder S, Roher HD, Deckart H, et al. Prognostic factors in MTC: Evaluation of 741 patients from the german MTC register. Clin Invest 1993 ; 71 : 7-12.
64. Modigliani E, Cohen R, Campos J, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 cases. Clin Endocrinol 1998 ; 48 : 265-73.
65. Scopsi L, Sampietro G, Baracchi I, Delbo R, Guillo M, Placucci M, et al. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. Cancer 1996 ; 78 : 2173-83.
66. Dottorini ME, Assi A, Sironi M, San Galli G, Spreafico G, Comombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996 ; 77 : 1556-65.
67. Franc B, Rosenberg-Bourgin M, Caillou B. Medullary thyroid carcinoma: Search for histological predictors of survival (109 proband cases analysis). Hum Pathol 1998 ; 29 : 1078-84.
68. Moers AJ, Landsvater RM, Schaap C, Jansen-Schilhorn Van Veen JM, De Valk IAJ, et al. Familial medullary thyroid carcinoma: Not a distinct entity? Genotype-phenotype correlations in a large family. Am J Med 1996 ; 101 : 635-41.